98%
921
2 minutes
20
Background: Some patients with heart failure (HF) have low natriuretic peptide (NP) levels. It is unclear whether specific populations are disproportionately excluded from participation in randomized clinical trials (RCT) with inclusion requirements for elevated NPs. We investigated factors associated with unexpectedly low NP levels in a cohort of patients hospitalized with HF, and the implications on racial diversity in a prototype HF RCT.
Methods: We created a retrospective cohort of 31,704 patients (age 72 ± 16 years, 49% female, 52% Black) hospitalized with HF from 2010 to 2020 with B-type natriuretic peptide (BNP) measurements. Factors associated with unexpectedly low BNP levels (<50 pg/mL) were identified using multivariable logistic regression models. We simulated patient eligibility for a prototype HF trial using specific inclusion and exclusion criteria, and varying BNP cut-offs.
Results: Unexpectedly low BNP levels were observed in 8.9% of the cohort. Factors associated with unexpectedly low BNP levels included HFpEF (aOR 3.76, 95% CI: 3.36, 4.20), obesity (aOR 1.96, 95% CI: 1.73, 2.21), self-identification as Black (aOR 1.53, 95% CI: 1.36, 1.71), and male gender (aOR 1.45, 95% CI: 1.31, 1.60). Applying limited clinical inclusion and exclusion criteria from PARAGLIDE-HF disproportionately excluded Black patients, with impairment in renal function having the greatest impact. Adding thresholds for BNP of ≥35, ≥50, ≥67, ≥100, and ≥150 pg/mL demonstrated the risk of exclusion was higher for Black compared to non-Black patients (RR = 2.03 [95% CI: 1.73, 2.39], 1.90 [95% CI: 1.68, 2.15], 1.63 [95% CI: 1.48, 1.81], 1.38 [95% CI: 1.28, 1.50], and 1.23 [95% CI: 1.15, 1.31], respectively).
Conclusions: Nearly 10% of patients hospitalized with HF have unexpectedly low BNP levels. Simulating inclusion into a prototype HFpEF RCT demonstrated that requiring increasingly elevated NP levels disproportionately excludes Black patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10592492 | PMC |
http://dx.doi.org/10.1016/j.ahj.2023.06.008 | DOI Listing |
Wien Klin Wochenschr
September 2025
3rd Medical Department with Cardiology and Intensive Care Medicine, Clinik Ottakring (Wilhelminenhospital), Montleartstraße 37, 1160, Vienna, Austria.
Background: Acute heart failure (AHF) significantly contributes to cardiovascular morbidity and mortality, bearing a substantial socioeconomic burden. While the dynamics of chronic heart failure have been extensively explored in global patient cohorts, comprehensive data specific to AHF remain limited.
Methods: This retrospective, single-center, real-world study comprises hospitalized patients with AHF, admitted to a tertiary care hospital in Vienna, Austria, between 1 January 2012 and 31 December 2019.
Ann Hematol
September 2025
Faculty of Medicine, Division of Hematology, Department of Internal Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
The development of pulmonary hypertension (PH) after splenectomy is one of the recently controversial issues. This study aims to investigate whether splenectomy itself is an independent risk factor for the development of PH or if the primary contributor to PH development is the underlying condition that necessitated splenectomy. This study was conducted prospectively.
View Article and Find Full Text PDFGen Physiol Biophys
September 2025
Department of Cardiology, The Fourth Affiliated Hospital of Harbin Medical University, Nangang District, Harbin, Heilongjiang, China.
Exosomes derived from various cells have been demonstrated to contribute to cardiac repair by regulating macrophage polarization in myocardial infarction. However, how exosomes secreted from cardiomyocytes under hypoxia-ischemia (Hypo-Exo) regulate macrophage polarization in the local tissues is elusive. This study aimed to determine the underlying mechanisms by which Hypo-Exo polarized M2 macrophages.
View Article and Find Full Text PDFJTCVS Open
August 2025
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minn.
Background: Proper risk stratification tools for patients with obstructive hypertrophic cardiomyopathy (oHCM) undergoing septal myectomy are lacking. Our objective was to assess the predictive value of preoperative N-terminal pro-brain natriuretic peptide (NT-proBNP) on perioperative outcomes and late survival in patients with oHCM undergoing transaortic septal myectomy.
Methods: Between 2008 and 2021, 834 patients with preoperative NT-proBNP measurements underwent septal myectomy.
Cureus
August 2025
Internal Medicine, University of Health Sciences, Lahore, PAK.
Heart failure remains a leading global health burden affecting over 64 million individuals worldwide, with limited effective acute management strategies. Carperitide, a recombinant form of human atrial natriuretic peptide, has been primarily used in Japan for acute heart failure treatment, but its clinical efficacy remains controversial. This systematic review and meta-analysis aimed to evaluate the clinical outcomes of carperitide in heart failure patients.
View Article and Find Full Text PDF